EVQLV Submits First Panel of Optimized Antibody Sequences

Apr 2, 2020 | Press Releases | 0 comments

Daniel Gigante

For the unaware, we are collaborating with ImmunoPrecise to develop treatment for the coronavirus. We recently submitted our first panel of optimized antibody sequences. See below.

EVQLV, has submitted their first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2. These DNA sequences were generated using computational antibody design, a method which combines mathematics, statistics, and computer science to identify high-affinity antibodies. The submitted antibody sequences were pre-screened by EVQLV’s artificial intelligence-driven algorithms, which work to maximize the resulting antibodies’ therapeutic potential while minimizing safety and manufacturing risks.IPA believes treatments for the new coronavirus are ideally generated using data from the newly emerged strain, in part as the spike protein from the 2019 virus has been shown to have a unique sequence that sets it apart from the 2002 SARS-CoV and SARS-related CoVs1.

You can read the entire press release here.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest